MDM2 antagonist clinical response association with a gene expression signature in acute myeloid leukaemia

British Journal of Haematology

Volumn 171, Issue 3, 2015, Pages 432-435

  Zhong, Hua ^a   Chen, Gong ^a   Jukofsky, Lori ^b   Geho, David ^b   Han, Sung Won ^c   Birzele, Fabian ^d   Bader, Sabine ^d   Himmelein, Lucia ^d   Cai, James ^b   Albertyn, Zayed ^b   Rothe, Mark ^e   Essioux, Laurent ^f   Burtscher, Helmut ^d   Middleton, Steven A ^b   Rueger, Ruediger ^d   Chen, Lin Chi ^b   Dangl, Markus ^d   Nichols, Gwen ^b   Pierceall, William E ^b  

^a Pharmaceutical Sciences   (United States)

^b Roche Innovation Center New York   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

^e Biometrics Product Development Roche Innovation Center New York   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Acute myeloid leukaemia; Diagnostic algorithm; Gene expression signature; MDM2 antagonist; TP53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTARABINE; IDASANUTLIN; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; PUMA PROTEIN; XERODERMA PIGMENTOSUM GROUP C PROTEIN; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE; IMIDAZOLINE DERIVATIVE; MDM2 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; APOPTOSIS; AREA UNDER THE CURVE; BBC3 GENE; CDKN2A GENE; CELL CYCLE ARREST; CLINICAL ARTICLE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; IC50; IN VITRO STUDY; LETTER; MALE; MDM2 GENE; PHASE 1 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; XPC GENE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMIDAZOLINES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 84944274644     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13411     Document Type: Letter

References (10)

1. Cancer Genome Atlas Research Network. (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukaemia. New England Journal of Medicine, 368, 2059-2074.
2. Chumakov, P.M. (2007) Versatile functions of TP53 protein in multicellular organisms. Biochemistry (Mosc), 72, 1399-1421.
3. Kojima, K., Konopleva, M., Samudio, I.J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., Tsao, T., Zeng, Z., Vassilev, L.T. & Andreeff, M. (2005) MDM2 antagonists induce TP53-dependent apoptosis in AML: implications for leukaemia therapy. Blood, 106, 3150-3159.
4. Manfredi, J.J. (2010) The Mdm2-TP53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes & Development, 24, 1580-1589.
5. Ray-Coquard, I., Blay, J.Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., Geho, D., Middleton, S.A., Vassilev, L.T., Nichols, G.L. & Bui, B.N. (2012) Effect of the MDM2 antagonist RG7112 on the TP53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. The Lancet. Oncology, 13, 1133-1140.
6. Shangary, S. & Wang, S. (2009) Small-molecule inhibitors of the MDM2-TP53 protein-protein interaction to reactivate TP53 function: a novel approach for cancer therapy. Annual Review of Pharmacology and Toxicology, 49, 223-241.
7. Thompson, T., Andreeff, M., Studzinski, G.P. & Vassilev, L.T. (2010) 1, 25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukaemia cells expressing wild-type TP53. Molecular Cancer Therapeutics, 9, 1158-1168.
8. Tovar, C., Graves, B., Packman, K., Filipovic, Z., Higgins, B., Xia, M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.H., Linn, M., Podlaski, F., Wovkulich, P., Vu, B. & Vassilev, L.T. (2013) MDM2 small-molecule antagonist RG7112 activates TP53 signaling and regresses human tumors in preclinical cancer models. Cancer Research, 73, 2587-2597.
9. Vassilev, L.T. (2007) MDM2 inhibitors for cancer therapy. Trends in Molecular Medicine, 13, 23-31.
10. Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N. & Liu, E.A. (2004) In vivo activation of the TP53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-848.